Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108
Article CAS PubMed Google Scholar
Birkmayer W, Hornykiewicz O (1961) The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787–788
Birkmayer W, Mentasti M (1967) Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes). Arch Psychiatr Nervenkr 210:29–35
Article CAS PubMed Google Scholar
Cadar D, Jellinger KA, Riederer P, Strobel S, Monoranu CM, Tappe D (2021) No Metagenomic evidence of causative viral pathogens in postencephalitic parkinsonism following encephalitis lethargica. Microorganisms 9:1716
Article CAS PubMed PubMed Central Google Scholar
Cardoso F, Goetz CG, Mestre TA, Sampaio C, Adler CH, Berg D, Bloem BR, Burn DJ, Fitts MS, Gasser T, Klein C, de Tijssen MAJ, Lang AE, Lim SY, Litvan I, Meissner WG, Möllenhauer B, Okubadejo N, Okun MS, Postuma RB, Svenningsson P, Tan LCS, Tsunemi T, Wahlström-Helgren S, Gershanik OS, Fung VSC, Trenkwalder C (2023) A Statement of the MDS on biological definition, staging, and classification of Parkinson’s disease. Mov Disord 9:259–266
Gad SN, Nofal S, Raafat EM, Ahmed AAE (2020) Lixisenatide reduced damage in hippocampus CA1 neurons in a rat model of cerebral ischemia-reperfusion possibly via the ERK/P38 signaling pathway. J Mol Neurosci 70:1026–1037
Article CAS PubMed Google Scholar
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39
Article CAS PubMed Google Scholar
Grünblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer’s disease. J Alzheimers Dis 16:627–634
Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Müller T, Wenning GK (2006) Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol 29:322–330
Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE (2024) A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23:191–204
Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S, Balazs E, Takacs K, Karadi K, Kovacs N (2015) Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord 21:1421–1426
Irfan H, Muneer SU, Maheshwari AB, Kumar N, Iftikhar S (2024) Lixisenatide in early Parkinson’s disease: efficacy, safety, and future directions: a correspondence. Neurosurg Rev 47:232
Isaacson SH, Pagan FL, Lew MF, Pahwa R (2022) Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord 7:100161
PubMed PubMed Central Google Scholar
Koller WC, Herbster G (1987) Adjuvant therapy of parkinsonian tremor. Arch Neurol 44:921–923
Article CAS PubMed Google Scholar
LeWitt PA, Stocchi F, Arkadir D, Caraco Y, Adar L, Perlstein I, Case R, Giladi N (2022) The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: findings from the ND0612 clinical development program. Front Neurol 13:1036068
Article PubMed PubMed Central Google Scholar
Malek N, Grosset DG (2015) Medication adherence in patients with Parkinson’s disease. CNS Drugs 29:47–53
Article CAS PubMed Google Scholar
Martinez-Nunez AE, LeWitt PA (2023) Drugs to the rescue: comparison of on-demand therapies for off symptoms in Parkinson’s disease. J Parkinsons Dis 13:441–451
Article PubMed PubMed Central Google Scholar
Meissner W, Reum T, Paul G, Harnack D, Sohr R, Morgenstern R, Kupsch A (2001) Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. Neurosci Lett 303:165–168
Article CAS PubMed Google Scholar
Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grunblatt E, Riederer P, Jacob C, Haron-Peretz J, Bashenko Y, Youdim MB, Mandel SA (2012) A molecular signature in blood identifies early Parkinson’s disease. Mol Neurodegener 7:26
Article CAS PubMed PubMed Central Google Scholar
Müller T (2021) View point: disease modification and cell secretome based approaches in Parkinson’s disease: are we on the right track? Biologics 15:307–316
PubMed PubMed Central Google Scholar
Müller T (2022) What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease? Expert Opin Pharmacother 23:745–750
Müller T, Möhr JD (2024) Negative findings from trials with NLY01 or deferiprone for Parkinson’s disease. Lancet Neurol 23:558–559
Müller T, Mueller BK, Riederer P (2021) Perspective: treatment for disease modification in chronic neurodegeneration. Cells 10:873
Article PubMed PubMed Central Google Scholar
Muller-Nedebock AC, Dekker MCJ, Farrer MJ, Hattori N, Lim SY, Mellick GD, Rektorova I, Salama M, Schuh AFS, Stoessl AJ, Sue CM, Tan AH, Vidal RL, Klein C, Bardien S (2023) Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease. NPJ Parkinsons Dis 9:110
Article PubMed PubMed Central Google Scholar
Mulroy E, Erro R, Bhatia KP, Hallett M (2024) Refining the clinical diagnosis of Parkinson’s disease. Parkinsonism Relat Disord 122:106041
Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR (2024) FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-24-0378
Nijhuis FAP, van den Heuvel L, Bloem BR, Post B, Meinders MJ (2019) The patient’s perspective on shared decision-making in advanced Parkinson’s disease: a cross-sectional survey study. Front Neurol 10:896
Article PubMed PubMed Central Google Scholar
Nyholm D, Johansson A, Lennernas H, Askmark H (2012) Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 19:820–826
Article CAS PubMed Google Scholar
Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S, Poewe W (2021) Continuous subcutaneous levodopa delivery for Parkinson’s disease: a randomized study. J Parkinsons Dis 11:177–186
Article CAS PubMed PubMed Central Google Scholar
Ossig C, Gandor F, Fauser M, Bosredon C, Churilov L, Reichmann H, Horne MK, Ebersbach G, Storch A (2016) Correlation of quantitative motor state assessment using a kinetograph and patient diaries in advanced PD: data from an observational study. PLoS ONE 11:e0161559
Article PubMed PubMed Central Google Scholar
Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, Simuni T, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs OS, Rosenfeld O, Sasson N, Yardeni T, Espay AJ (2021) Subcutaneous levodopa infusion for Parkinson’s disease: 1-year data from the open-label BeyoND study. Mov Disord 36:2687–2692
留言 (0)